1.7mg semaglutide to tirzepatide vs. for Weight Loss Semaglutide vs. Tirzepatide: Which GLP-1

The anti-obesity drug semaglutide may lower the risk of death from COVID-19, cardiovascular disease, and all causes, according to a randomized controlled trial published late last week in the Journal of the American College of Cardiology ( JACC )

Timelines can be longer if insurance verification or prior authorization is involved

The U.S Food and Drug Administration drug labels for GLP-1 receptor agonists include a warning that acute pancreatitis has been observed in patients and that treatment should be discontinued promptly if acute pancreatitis is suspected

Losing just 5-10% of body weight often produces significant symptom improvement

Patrick Carroll, Chief Medical Officer of Hims & Hers